pentoxifylline has been researched along with Pneumonia, Viral in 8 studies
Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Having the potential role in suppressing inflammation, immune modulation, antiviral and improving respiratory symptoms, this review discusses the potential role of methylxanthine drugs like pentoxifylline and caffeine in the management of COVID-19 patients." | 5.05 | Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. ( Al-Mahmood Siddiquee, A; Hashemian, F; Monji, F, 2020) |
| "We have previously described that pentoxifylline alone, or in combination with oxypurinol, reduces the systemic inflammation caused by experimentally-induced pancreatitis in rats." | 3.96 | Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the ( Franco, L; López-Iranzo, FJ; López-Rodas, AM; López-Rodas, G, 2020) |
| "Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV)." | 2.66 | Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? ( Fattahi, N; Goodarzi, A; Hanifiha, M; Mozafarpoor, S; Sadeghzadeh-Bazargan, A; Seirafianpour, F, 2020) |
| "Although most patients with coronavirus disease 2019 (COVID-19) have a good prognosis, in some cases, the disease progresses rapidly, and the mortality rate is high." | 2.66 | Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. ( Amezcua-Guerra, LM; Arias-Mendoza, A; González-Pacheco, H; Sandoval, J, 2020) |
| "Pentoxifylline is an immunomodulator with anti-inflammatory properties." | 2.66 | Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. ( Arnold, AD; Arnold, J; Hendry, BM; Manglam, V; Rosen, SD; Sangwaiya, A; Stafford, N, 2020) |
| "Counterproductive lung inflammation and dysregulated thrombosis contribute importantly to the lethality of advanced COVID-19." | 1.56 | Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. ( Barroso-Aranda, J; DiNicolantonio, JJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feily, A | 1 |
| Daneshpay, K | 1 |
| Alighadr, A | 1 |
| Seirafianpour, F | 1 |
| Mozafarpoor, S | 1 |
| Fattahi, N | 1 |
| Sadeghzadeh-Bazargan, A | 1 |
| Hanifiha, M | 1 |
| Goodarzi, A | 1 |
| Assimakopoulos, SF | 1 |
| Seintis, F | 1 |
| Marangos, M | 1 |
| DiNicolantonio, JJ | 1 |
| Barroso-Aranda, J | 1 |
| González-Pacheco, H | 1 |
| Amezcua-Guerra, LM | 1 |
| Sandoval, J | 1 |
| Arias-Mendoza, A | 1 |
| Hendry, BM | 1 |
| Stafford, N | 1 |
| Arnold, AD | 1 |
| Sangwaiya, A | 1 |
| Manglam, V | 1 |
| Rosen, SD | 1 |
| Arnold, J | 1 |
| López-Iranzo, FJ | 1 |
| López-Rodas, AM | 1 |
| Franco, L | 1 |
| López-Rodas, G | 1 |
| Monji, F | 1 |
| Al-Mahmood Siddiquee, A | 1 |
| Hashemian, F | 1 |
4 reviews available for pentoxifylline and Pneumonia, Viral
| Article | Year |
|---|---|
Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
Topics: Betacoronavirus; Chemotherapy, Adjuvant; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.
Topics: Anti-Inflammatory Agents; Antioxidants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; C | 2020 |
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pento | 2020 |
Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
4 other studies available for pentoxifylline and Pneumonia, Viral
| Article | Year |
|---|---|
COVID-19: Pentoxifylline as a potential adjuvant treatment.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combinatio | 2020 |
Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Blood Coagulation Disorders; Coronavirus Infecti | 2020 |
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
Topics: Adenosine A2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; C | 2020 |
Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
Topics: Acute Disease; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome | 2020 |